Therapeutic/prophylactic agent for prostate cancer
AssigneeGenomidea Inc.
InventorsYasufumi Kaneda, Yoshifumi Kawaguchi, Toshimitsu Itai
Life of this patent
Estimating the term…
Abstract
Provided are a novel therapeutic agent and therapeutic method for prostatic cancers. More specifically, a prostatic cancer therapeutic/prophylactic agent having a viral envelope vector, particularly a Sendai viral envelope vector, as an active ingredient, the therapeutic/prophylactic agent which is an apoptosis induction promoter, the therapeutic/prophylactic agent used for prostatic cancers whose androgen susceptibility has been partially or completely reduced, and a melanoma therapeutic/prophylactic agent containing a Sendai viral envelope vector as the only active ingredient, and the like are provided.
Claims30
A prostatic cancer therapeutic/prophylactic agent containing a viral envelope as an active ingredient.
9-15. (canceled)
A method of treating/preventing prostatic cancer, comprising administering to an individual in need thereof an effective amount of a viral envelope to a prostatic cancer patient or a person at a risk of contracting prostatic cancer.
An inducer of prostatic cancer cell apoptosis, comprising a viral envelope as an active ingredient.
A method of inducing prostatic cancer cell apoptosis, comprising administering an effective amount of a viral envelope to a prostatic cancer patient or a person at a risk of contracting prostatic cancer.
22-23. (canceled)
An agent for the treatment/prophylaxis of melanoma, comprising the Sendai viral envelope (HVJ-E) as the only active ingredient.
25-28. (canceled)
A method of treating/preventing melanoma, comprising administering an effective amount of the Sendai viral envelope (HVJ-E) as the only active ingredient for treating/preventing melanoma to a melanoma patient or a person at a risk of contracting melanoma.
(canceled)
A pharmaceutical composition comprising the Sendai viral envelope (HVJ-E) as the only active ingredient for producing a therapeutic/prophylactic agent for melanoma.
Dependencies are inferred from the claim text.